Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Common Equity (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed Common Equity for 8 consecutive years, with $61.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity rose 3.35% year-over-year to $61.6 million, compared with a TTM value of $61.6 million through Sep 2025, up 3.35%, and an annual FY2024 reading of $22.1 million, down 56.65% over the prior year.
  • Common Equity was $61.6 million for Q3 2025 at X4 Pharmaceuticals, up from $4.0 million in the prior quarter.
  • Across five years, Common Equity topped out at $105.1 million in Q1 2021 and bottomed at $1.0 million in Q1 2024.
  • Average Common Equity over 5 years is $55.0 million, with a median of $61.6 million recorded in 2025.
  • The sharpest move saw Common Equity plummeted 98.0% in 2024, then skyrocketed 2114.67% in 2025.
  • Year by year, Common Equity stood at $64.4 million in 2021, then increased by 14.96% to $74.1 million in 2022, then crashed by 30.99% to $51.1 million in 2023, then crashed by 56.65% to $22.1 million in 2024, then soared by 178.2% to $61.6 million in 2025.
  • Business Quant data shows Common Equity for XFOR at $61.6 million in Q3 2025, $4.0 million in Q2 2025, and $22.9 million in Q1 2025.